News
October 1, 2018
IntegriChain’s Dave Weiss to Chair 340B Track at Medicaid Drug Rebate Program Summit
340B Is Key Focus of 2018 MDRP Agenda
Pharma Brands Seeking to Monitor 340B Duplication & Diversion
Philadelphia, PA, October 1, 2018 – IntegriChain, a leading life sciences commercial analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation, adherence, and persistence, today announced that Dave Weiss, Executive Director of Industry Solutions and industry expert on 340B analytics, will chair the 340B Track at the Medicaid Drug Rebate Program Summit (MDRP). The MDRP 340B track is slated for October 2 from 1:45 pm to 5:20 pm, and 340B sessions dominate this year’s MDRP agenda overall.
“The 340B program has experienced explosive growth in the past several years, and the number of covered entities, contract pharmacies, and participating hospitals is higher than ever,” said Weiss. “Recent research shows that the original intent of the program, subsidizing care for underserved patient populations, is not being fulfilled and program non-compliance is increasing overall healthcare costs. The pharma industry is clearly searching for a solution until new regulations address these issues. A number of leading brands have recently initiated projects with us to identify and monitor 340B duplicate discounts and diversions tied to Medicaid and suspicious purchase volumes so that can have better, more productive reviews with their 340B customers.”
About IntegriChain
IntegriChain is a life sciences commercial analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation, adherence, and persistence. Our ICyte Platform and solutions uniquely focus on what happens after the patient and provider commit to therapy. More than 140 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA; the Access Management Operations center is in Ambler, PA; and the Patient Services Center is in Atlanta, GA. For more information, visit www.integrichain.com or follow us on Twitter @IntegriChain and LinkedIn.
Contact
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com
